VivoSeq
Oncology

Stomach Neoplasms

8

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Stomach Neoplasms is an early-stage landscape with 8 programs across 3 companies. The most active players are AstraZeneca, Teva, Kenvue Brands. 2 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

4 programs

Phase 2Teva logo

Teva

1 program

Phase 2K

Kenvue Brands

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

63%

Small molecule

5 of 8 classified programs — the dominant modality here.

38%ALL OTHERSAntibody–drug conjugate225%Monoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

3

clinical trials

Not yet recruiting2 · 67%
Recruiting1 · 33%

Clinical Trials

Trial Activity

A Phase IV, Multicenter, Double-blind, Randomized Controlled Trial to Evaluate the Superiority of Maxigesic® Over Standard Analgesia in Patients Undergoing Radical Gastrectomy
Not yet recruiting·YYonsei University·Approved·NCT07687394·160 enrolled
A Phase II Platform Trial of Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (Neo-VIKTORY)
Recruiting·—·Phase 2·NCT06630130·100 enrolled
A Comparative Study of One-Click Autofocus Versus Segmented Focus Techniques Under Magnifying Endoscopy for Gastric Diseases: A Tandem Randomized Controlled Trial
Not yet recruiting·SShandong University·Preclinical·NCT07664813·93 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)